Becton Dickinson and Co presents a defensive quality profile with a beta of 0.2, positioning it among the least volatile equities in the health care sector. The company's current valuation at 39.78x trailing earnings sits at a premium multiple despite recent profitability headwinds, with earnings per share declining 24.84% year-over-year to $3.94. Trading at $165.62, the stock has retreated from its 52-week high of $187.35, creating a $45.6 billion market capitalization that reflects its established presence in medical technology.

The fundamental screening reveals several structural strengths. Gross margins of 46.99% demonstrate pricing power in specialized medical devices and diagnostics, while the debt-to-equity ratio of 0.76 indicates manageable leverage for a capital-intensive manufacturer. The current ratio of 1.11 provides adequate liquidity coverage, and the price-to-book multiple of 2.1 suggests reasonable valuation relative to tangible assets given the company's market position.

Profitability metrics highlight operational challenges requiring attention. Return on equity of 4.54% and return on assets of 2.11% fall below typical benchmarks for established medical device leaders, while the net margin of 5.33% compresses despite healthy gross profitability. Revenue growth of 2.39% year-over-year indicates modest organic expansion, potentially constrained by procedure volume dynamics and competitive pressures.

Relative to peers including Abbott Laboratories (ABT), Stryker (SYK), and Intuitive Surgical (ISRG), systematic analysis flags BDX's lower volatility profile and diversified revenue base across diagnostics and intervention platforms. The price-to-sales ratio of 2.12 positions the company at a moderate valuation within the sector, though return metrics trail higher-growth surgical robotics and diagnostic innovators in the competitive set.